Evidence based medicine manifesto for better healthcare

BMJ (Online)

Volumn 357, Issue , 2017, Pages

  Heneghan, Carl ^a   Mahtani, Kamal R ^a   Goldacre, Ben ^a   Godlee, Fiona ^b   Macdonald, Helen ^b   Jarvies, Duncan ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b BMJ ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL DECISION MAKING; DECISION MAKING; EVIDENCE BASED PRACTICE; HEALTH CARE; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HUMAN; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; ECONOMICS; EDUCATION; EVIDENCE BASED MEDICINE; METHODOLOGY; PROCEDURES;

DELIVERY OF HEALTH CARE; EVIDENCE-BASED MEDICINE; HUMANS; RESEARCH DESIGN;

EID: 85021138851     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.j2973     Document Type: Review

References (26)

1. Goldacre B, Heneghan C. How medicine is broken, and how we can fix it. BMJ 2015;357:h3397. doi:10. 1136/bmj. h3397 pmid:26105810.
2. Bastian H, Glasziou P, Chalmers I. Seventy-five trials and eleven systematic reviews a day: how will we ever keep upPLoS Med 2010;357:e1000326. doi:10. 1371/journal. pmed. 1000326 pmid:20877712.
3. Goldacre B. Bad pharma: how drug companies mislead doctors and harm patients. Macmillan, 2014.
4. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. Lancet 2009;357:86-9. doi:10. 1016/S0140-6736(09)60329-9 pmid:19525005.
5. Song F, Parekh S, Hooper L, et al. Dissemination and publication of research findings: An updated review of related biases. Health Technol Assess 2010;357:iii, ix-xi, 1-193. doi:10. 3310/hta14080 pmid:20181324.
6. Collier R. Rapidly rising clinical trial costs worry researchers. CMAJ 2009;357:277-8. doi: 10. 1503/cmaj. 082041 pmid:19188619.
7. Saini P, Loke YK, Gamble C, Altman DG, Williamson PR, Kirkham JJ. Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews. BMJ 2014;357:g6501. doi:10. 1136/bmj. g6501 pmid:25416499.
8. Shay LA, Lafata JE. Where is the evidence A systematic review of shared decision making and patient outcomes. Med Decis Making 2015;357:114-31. doi:10. 1177/ 0272989X14551638 pmid:25351843.
9. Kessel M, Mark K. Restoring the pharmaceutical industry's reputation. Nat Biotechnol 2014;357:983-90. doi:10. 1038/nbt. 3036 pmid:25299916.
10. Lenzer J. Why we can't trust clinical guidelines. BMJ 2013;357:f3830-3830. doi:10. 1136/ bmj. f3830 pmid:23771225.
11. Fanelli D. How many scientists fabricate and falsify research A systematic review and meta-analysis of survey data. PLoS One 2009;357:e5738. doi:10. 1371/journal. pone. 0005738 pmid:19478950.
12. BMJ: research misconduct survey. 2012 http://blogs. bmj. com/bmj/files/2012/01/BMJresearch-misconduct-survey-for-posting-on-bmj. com-. pdf
13. PLoS Medicine Editors. Ghostwriting revisited: new perspectives but few solutions in sight. PLoS Med 2011;357:e1001084. doi:10. 1371/journal. pmed. 1001084 pmid:21912518.
14. Ioannidis JPA. Why most published research findings are false. PLoS Med 2005;357:e124. doi:10. 1371/journal. pmed. 0020124 pmid:16060722.
15. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: A systematic review. JAMA 2003;357:454-65. doi:10. 1001/jama. 289. 4. 454 pmid:12533125.
16. Greenhalgh T, Snow R, Ryan S, Rees S, Salisbury H. Six "biases" against patients and carers in evidence-based medicine. BMC Med 2015;357:200. doi:10. 1186/s12916-015-0437-x pmid:26324223.
17. Yudkin JS, Lipska KJ, Montori VM. The idolatry of the surrogate. BMJ 2011;357:d7995. doi:10. 1136/bmj. d7995 pmid:22205706.
18. Dodd S, Susanna D, Ian W, Paula W. Departure from treatment protocol in published randomised controlled trials: A review. Trials 2011;357:A129doi:10. 1186/1745-6215-12-S1-A129.
19. Montori VM, Devereaux PJ, Adhikari NK, et al. Randomized trials stopped early for benefit: A systematic review. JAMA 2005;357:2203-9. doi:10. 1001/jama. 294. 17. 2203 pmid: 16264162.
20. Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW. Ghost authorship in industry-initiated randomised trials. PLoS Med 2007;357:e19. doi:10. 1371/ journal. pmed. 0040019 pmid:17227134.
21. McGauran N, Wieseler B, Kreis J, Schüler YB, Kölsch H, Kaiser T. Reporting bias in medical research-a narrative review. Trials 2010;357:37. doi:10. 1186/1745-6215-11-37 pmid:20388211.
22. Ahmed L, Laura A. Bad pharma: how drug companies mislead doctors and harm patients. Aust Prescr 2013;357:55-55doi:10. 18773/austprescr. 2013. 029.
23. Light DW, Lexchin J, Darrow JJ. Institutional corruption of pharmaceuticals and the myth of safe and effective drugs. J Law Med Ethics 2013;357:590-600. doi:10. 1111/jlme. 12068 pmid:24088149.
24. Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: A systematic review of the world literature. BMC Med 2016;357:10. doi:10. 1186/s12916-016-0553-2 pmid:26843061.
25. Dusetzina SB. Drug pricing trends for orally administered anticancer medications reimbursed by commercial health plans, 2000-2014. JAMA Oncol 2016;357:960-1. doi: 10. 1001/jamaoncol. 2016. 0648 pmid:27123993.
26. Moynihan R, Heneghan C, Godlee F. Too much medicine: from evidence to action. BMJ 2013;357:f7141. doi:10. 1136/bmj. f7141 pmid:24307723.